# Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis

> **NCT02912897** · PHASE1 · RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 7 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Cellular therapy with EBV specific autologous CTL infusion

## Key facts

- **NCT ID:** NCT02912897
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-26
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02912897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02912897, "Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02912897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*